Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

The landscape of intrinsically disordered proteins in Leishmania parasite: Implications for drug discovery.

International journal of biological macromolecules·2024
Same author

Pharmacophore-guided drug design using LdNMT as a model drug target for leishmaniasis.

Journal of biomolecular structure & dynamics·2023
Same author

Recent Advances in the Modeling of Alzheimer's Disease.

Frontiers in neuroscience·2022
Same author

Clinical research in dementia: A perspective on implementing innovation.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2022
Same author

Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia.

Journal of Alzheimer's disease : JAD·2022

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

薬物開発

Bengt Winblad1,2, Lisha Wang1, Banesh Sooram1

  • 1Division of Neurogeriatrics, Karolinska Institutet, Solna, Stockholm, Sweden.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
まとめ
この要約は機械生成です。

新規プロテオリシス標的キメラ（PROTAC）は、アルツハイマー病におけるタウ凝集体分解の可能性を示す。

キーワード:
プロタックタウアルツハイマー病神経変性疾患薬物開発

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学分野:

  • 神経科学
  • 薬理学
  • 生化学

背景:

  • 神経細胞内のタウ凝集体は、アルツハイマー病（AD）の主要な病理学的特徴である。
  • ユビキチン・プロテアソーム系のようなタンパク質分解経路の障害は、タウ蓄積を悪化させる。
  • プロテオリシス標的キメラ（PROTAC）は、標的タンパク質分解を誘導するための新しい戦略を提供する。

研究 の 目的:

  • タウ分解を促進するための新規低分子PROTACを開発すること。
  • PROTACsをADの治療アプローチとして調査すること。

主な方法:

  • PROTACsのインシリコライブラリ生成および三者複合体形成モデリング。
  • 安定性と透過性に関する薬物動態特性および分子動力学シミュレーションの予測。
  • プロテアソーム/オートファジー阻害を用いた細胞モデル（SH-SY5Y、初代神経細胞）におけるPROTACsの評価（ウェスタンブロット、免疫蛍光、プロテアソーム/オートファジー阻害）。

主要な成果:

  • 計算モデリングにより、三者複合体形成能が強化された25を超えるPROTACが同定された。
  • 薬物動態予測では、いくつかのPROTAC候補について、良好な経口バイオアベイラビリティ、脳透過性、および低毒性が示唆された。
  • インビトロ研究では、PROTACsが初代神経細胞におけるAβ42誘発性タウ過剰リン酸化を逆転させることが示された。

結論:

  • 新規低分子PROTACは、タウ凝集体を効果的に分解する可能性を示す。
  • PROTAC技術は、ADおよびその他の神経変性疾患の画期的な治療法開発に有望である。